Dr. Frances Shepherd CV - (NCRI) is

CURRICULUM VITAE
FRANCES ALICE SHEPHERD
February, 2012
BIOGRAPHICAL INFORMATION:
Business Address: Princess Margaret Hospital
610 University Avenue, 5-104
Toronto, Ontario, Canada M5G 2M9
(416) 946-4522 FAX (416) 946-6546
2. DEGREES: M.D., University of Toronto, 1970
FRCPC, Internal Medicine, 1975
FRCPC, Hematology, 1975
3. EDUCATION: 1951-1964 Branksome Hall School
Head Girl 1963-1964
1964-1970 University of Toronto
Faculty of Medicine
4. POST GRADUATE TRAINING:
1970-1971 Rotating Intern, Royal Victoria Hospital, Montreal
1971-1972 Junior Assistant Resident in Medicine, Royal Victoria Hospital
1972-1973 Senior Assistant, Resident in Medicine, Royal Victoria Hospital
July to Dec. 1973 Resident in Laboratory, Hematology, Mount Sinai Hospital,
Toronto
Jan. to June 1974 Assistant Resident in Hematology, Toronto General Hospital
1974-1975 Resident in Hematology, Toronto Western Hospital
1975-1977 Leukemia Research Fellow, Princess Margaret Hospital, Toronto
5. RECENT EMPLOYMENT:
2001-Present Scott Taylor Chair in Lung Cancer Research
1998-Present Staff Physician, Princess Margaret Hospital, University Health
Network
1994-Present Professor of Medicine, University of Toronto
1996-2002 Director, Division of Medical Oncology, Faculty of Medicine,
Department of Medicine, University of Toronto
1988-1996 Head, Section of Medical Oncology, Division of
Hematology/Oncology, The Toronto Hospital, General & Western
Divisions
6. PRESENT & SELECT PAST PROFESSIONAL AFFILIATIONS AND
ACTIVITIES:
2010-Present Member, American Society of Clinical Oncology, Board of Directors
2010-Present Member Executive, American Society of Clinical Oncology, Board of Directors,
Cancer Prevention Committee
2009-Present Chair, European Organization for Research and Treatment of Cancer,
Protocol Review Committee
2009-Present Member, European Organization for Research and Treatment of Cancer,
Board of Directors
1

2009-Present Member, Executive Committee of the National Cancer Institute of Canada
Clinical Trials Group, Lung Cancer Committee
2009-Present Member, Editorial Board of Journal of Clinical Oncology
2008-Present Associate Editor, Therapeutic Advances in Medical Oncology
2003-Present Member, Correlative Science and Tumor Biology Lung Cancer Review
Committee of the Nastional Cancer Institute of Canada Clinical Trials Group
2005-Present Member, Clinical Trials Awards and Advisory Committee, Cancer Research
UK Medical Research Council
1989-2008 Chair, Lung Cancer Site Committee of the National Cancer Institute Canada,
Clinical Trials Group
2007-2009 President, International Association for the Study of Lung Cancer
2005-2007 Past President, International Association for the Study of Lung Cancer
2005-2007 Chair, American Society of Clinical Oncology, Publications Committee
2003-2007 Member, International Association for the Study of Lung Cancer Staging
Committee
2003-2007 Chair, International Association for the Study of Lung Cancer Staging
Committee, Small Cell Lung Cancer Subcommittee
7. CURRENT ADMINISTRATIVE POSITIONS:
1. University Committees:
1995-Present Member for Research, University of Toronto, Division of Medical Oncology
Executive Committee
1989-Present Member for Thoracic Oncology, University of Toronto, Division of Respirology
Executive Committee
2. Hospital Committees:
2009-Present Member, Princess Margaret Hospital Fellowship Committee
2008-Present Member, University Health Network Clinical Research Oversight Committee
2005-Present Member, Clinical Research Unit Executive Committee, Princess Margaret
Hospital
2005-Present Member, Department of Medical Oncology and Hematology Executive
Committee, Princess Margaret Hospital
2002-Present Team Leader, Fundraising Committee of University Health Network for Lung
Cancer
8. RECENT AWARDS LAST 5 YEARS:
2007 International Association for the Study of Lung Cancer Scientific Award
2007 Order of Ontario
2008 Premier of Ontario Summit Award for Medical Research
2008 Princess Margaret Hospital, Department of Medical Oncology Research Award
2009 Princess Margaret Hospital, Department of Medical Oncology Research Award
2009 National Cancer Institute of Canada, Cosbie Memorial Award and Lecture
2009 Marvin Steinhardt Award and Lecture
2009 University Health Network Inventor of the Year Award
2011 Alunna of the Year Award, Branksome Hall School
2011 Ontario Cancer Institute Till and Mccullough Translational Paper of the Year Award
2011 University of Toronto, Department of Medicine, Division of Medical Oncology Research
Award
2012 British Thoracic Oncology Group International Award for Contributions to Lung Cancer
Research
2

2012 Royal College of Physicians and Surgeons of Canada Whiteman Award and Visiting
Professorship
2012 Queen Elizabeth II Jubilee medal
10. RESEARCH GRANT SUPPORT LAST 5 YEARS: (Peer-reviewed, non-industry grants
shaded in gray)
RESEARCH AREA
Genomic and Proteomic biomarkers
of response to treatment with small
molecule Epidermal Growth Receptor
Inhibitors in non-small cell lung
cancer
Translating the results of clinical
trials of radio/chemotherapy into
improved health outcomes in the
general population
Phase III trial of Taxotere versus
Iressa as second-line chemotherapy
for non-small cell lung cancer
INTEREST
National Cancer Institute of Canada
Clinical Trials Group
Genomic biomarkers of response to
treatment with erlotinib, a small
molecule tyrosine kinase inhibitor of
the epidermal growth factor receptor
inhibitor in NSCLC
A Phase randomized II trial of
ZD6474 or placebo in responding to
patients with SCLC
National Cancer Institute of Canada
Clinical Trials Group
Phase III trial of Tarceva in 3 rd -line
treatment of NSCLC
Phase III trial of Taxotere +/-
Topotecan in 2 nd -line NSCLC
ROLE
GRANTING
AGENCY
Co-investigator OCRN
(03-APR-0324)
Co-Investigator OCRN
(02-NOV-0266)
Local
Principal
Investigator
Dr. Pater PI,
Dr. Shepherd
PI for Lung
Site
Principal
Investigator
Local
Principal
Investigator
Dr. Pater PI,
Dr. Shepherd
PI for Lung
Site
Principal
Investigator
PERIOD
FUNDING
2003-2006 $526,560.00
2004-2007 $848,643.60
AstraZeneca 2004-2006 $190,000
NCI-US 2004-2005
2005-2006
2006-2007
2007-2008
2008-2009
Jacqueline
Seroussi
Memorial
Foundation for
Cancer Research
$3,094,228
$3,335,209
$3,674,024
$3,717,333
$3,717,333
2004-2006 $185,000
NCIC-CTG 2003-2006 $36,000
NCI Canada 2004
2005
2006
2007
2008
$3,717,333
$5,117,333
$5,117,333
$5,117,333
$5,117,333
NCIC CTG 2001-2004 $132,000 total
Co-investigator Pfizer 2004-2006 $30,000
3

Molecular prognostic markers in early
stage NSCLC
Genomic and proteomic biomarkers
of response to EGFR inhibitors in
NSCLC
Gene expression profiling and
molecular classification of lung
cancer
Phase III trial of induction
chemotherapy vs surgery alone for
Stage III NSCLC
Phase III trial of gemcitabine/cisplatin
+/-LY-293111 in NSCLC
Phase II trial of ZD6474 vs placebo in
responding patients with SCLC
Novel molecular prognostic markers
and potential therapeutic targets in
non-small cell lung cancer
Phase II trial of gemcitabine/cisplatin
+/- cetuximab in patients with
advanced NSCLC
Phase III trial of placebo versus Iressa
in advanced NSCLC
Phase I trial of paclitaxel and
carboplatin and AZD2171 in
advanced NSCLC NCIC IND.171
Phase I trial of gemcitabine and
cisplatin increasing doses of
AZD2171 in advanced NSCLC NCIC
IND.175
Genomic profiles of lung cancer that
predict prognosis and response to
adjuvant chemotherapy.
Phase I trial of paclitaxel and
carboplatin +/- AZD2171 in advanced
NSCLC NCIC BR.24
Molecular predictors of outcome in
BR.19 a phase III trial of adjuvant
gefitinib post resection of early stage
non-small cell lung cancer
Randomized Phase II trial of RAD001
in advanced NSCLC
Co-investigator
Dr. M Tsao PI
Co-investigator
Dr. M Tsao PI
Co-investigator
Dr. MS Tsao PI
OCRN
(02-MAY-0132)
OCRN
(02-APR-0324)
Co-Investigator NCI US and
CTEP
2003-2006 $429,600.00
2003-2006
$526,000.00
NCIC 2004-2009 $750,000.00
2002-2004 $18,00.00
Co-investigator Eli Lilly 2003-2004 Per case
funding
$48,000 total
Co-Investigator
Institutional PI
Co-applicant
Dr. MS Tsao PI
NCIC CTG 2004-2006 $30,000.00
NCIC
Grant #015184
International PI Bristol Myers
Squibb
Co-Investigator
Institutional PI
2004-2009 $150,000/ year
x 5 yrs
2005 Per patient
funding
$36,000.00
Novartis 2005-2006 Per patient
funding
$24,000.00
Co-investigator NCIC CTG 2005-2006 Per patient
funding
$12,000.00
Co-investigator NCIC CTG 2005-2006 Per patient
funding
$24,000.00
Co-Investigator
Dr.M-S Tsao PI
Local Principal
Investigator
Co-Investigator
Dr. I. Lorimer PI
Local Principal
Investigator
OCRN
04-May-00133
2005 -2008 $489,900
NCIC CTG 2006-2008 Per patient
funding
$240,000.00
OCRN
05NOV 00186
2006-2009 $476, 640
Novartis 2005-2006 $130,000.00
Randomized Phase II trial of Local Principal Millenium 2005-2007 Per patient
4

docetaxel +/- Velcade in advanced
NSCLC
Randomized Phase II docetaxel +/-
ZD6474 in advanced NSCLC
Randomized Phase III study of
BLP25 Vaccine in stage III NSCLC
Randomized Phase III trial of
adjuvant Tarceva in resected NSCLC
Randomized Phase III trial of
chemotherapy +/- bevacizimab in
resected NSCLC
SNPs as predictors of response to
erlotinib in non-small cell lung cancer
in NCIC CTG trial BR.21
Premier of Ontario Summit Award
for Medical Research
Adoption of Adjuvant
Chemotherapy for NSCLC in
Ontario: A Population-based
Outcomes Study
Novel therapeutic targets for lung
cancer
Early detection of lung cancer – a
pan-Canadian study
Prognostic and predictive markers
in early stage lung cancer
Integrated molecular pathology of
targeted cancer therapy in lung
cancer
Boeringer Ingelheim innovation
award for molecular profiling of
lung cacner
Randomized Phase III trial of
chemotherapy +/- ARQ197 in
advanced NSCLC
Randomized Phase III trial of
chemotherapy +/- BSI-201 in
advanced NSCLC
CANTARISK study of VTE in lung
and GI cancer patients receiving
chemotherapy
Investigator Pharmaceuticals funding
$45,000.00
Local Principal
Investigator
International
Principal
Investigator
International
Principal
Investigator
Co-Investigator NCI-US
CTEP
Co-Investigator
Dr. G. Liu PI
Principal
Investigator
Co-Investigator
C. Booth PI
Co-Investigator
Dr. Tsao PI
Co-Investigator
Drs. Tsao and
Lam co-PIs
Co-Investigator
Dr. Tsao PI
Co-Investigator
Dr. Tsao PI
Principal
Investigator
Co-investigator
Local Principal
Investigator
Co- Principal
Investigator &
International
Steering
Committee
member
Co- Principal
Investigator &
International
Steering
Committee
member
AstraZeneca 2006-2007 $60,000.00 to
date
Merck 2006-2009 $30,000.00 to
date
Roche 2006-2010 $60,000.00
2008-2012 About to Open
OICR 2008-2011 $130,000.00
Ontario Gov’t 2008-2013 $5,000,000.00
CIHR 2009-2012 $357,109.00
OICR 2009-2012 $225, 849.99
Terry Fox
Research
Institute
2008-2013 $1,331,188.00
CCSRI 2009-2014 $138,000.00
Ontario
Research
Fund for
Research
Excellence
Boeringher
Ingelheim
Arqule 2010-
Sanofi-
Aventis
Sanofi-
Aventis
11. PUBLICATIONS LAST 5 YEARS OUT OF A TOTAL OF 390:
2009-2014 $935,109.00
2010-2013 $1,500,000.00
2010-
2011-2012
5

1. Kassam F, Shepherd FA, Johnston M, Visbal A, Feld R, Darling G, Keshavjee S, Pierre
A, Waddell T, Leighl NB. Referral Patterns for Adjuvant Chemotherapy in Patients with
Completely Resected Non-Small Cell Lung Cancer. Journal of Thoracic Oncol 2 (1): 39-
43, 2007.
2. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH,
Shulman L, Shepherd FA, Deschamps C, Livingston RB, Gandara D. Journal of Clin
Oncol 25 (3): 313-318, 2007.
3. Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S,
deAlbuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton
D, von Pawel J, Reck M, Shepherd FA. Symptom Improvement in Lung Cancer Patients
Treated with Erlotinib: Quality of life Analysis of the National Cancer Institute of
Canada Clinical Trials Group Study BR.21. J Clin Oncol 24(24: 3831-3837, 2007
4. Blackhall FH, Shepherd FA. Small Cell Lung Cancer and Targeted Therapies. Curr Opin
Oncol. 19 (2): 103-108, 2007
5. Seve P, Lai R, Ding K, Winton T, Butts C, Mackey J, Dumontet C, Dannagh L, Aviel-
Ronen S, Seymour L, Whitehead M, Tsao MS, Shepherd FA, Reiman T. Class III Beta-
Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in
Operable Non-Small Cell lung Cancer: Analysis of NCIC CTG JBR.10. Clin Cance Res
13 (3): 994-999, 2007.
6. Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer
Incidence Among Canadian Kidney Transplant Recipients. Am J Transplant 2007; (4):
941-8.
7. Clark GM, Zabrowski DM, Culberston JL, Whitehead M, Savoie M, Seymour L,
Shepherd FA. Clinical Utility of Epidermal Growth Factor Receptor Expression for
Selecting Patients with Advanced Non-Small Cell Lung Cancer for Treatment with
Erlotinib. J Thorac Oncol. 2006 Oct 1 (8): 837-846.
8. Cheng S, Evans WK, Stys-Norman D, Shepherd FA; the Lung Cancer Disease Site
Group of Cancer Care Ontario’s Program in Evidence-Based Care. Chemotherapy for
Relapsed Small Cell Lung Cancer: A Systematic Revue and Practice Guideline. J Thorac
Oncol. 2007 Apr: 2 (4): 348-354.
9. Benamore R, Shepherd FA, Leighl N, Pintilie M, Patel M, Feld R, Herman S. Does
Intensive Follow-Up Alter Outcome in Patients with Advanced Lung Cancer? J Thorac
Oncol. 2007 Apr: 2 (4): 273-281.
10. Pepe C, Hasan B, Winton TL, Seymour L, Graham B, Livingston RB, Johnson DH,
Rigas JR, Ding K, Shepherd FA. Adjuvant Vinorelbine and Cisplatin in Elderly Patients:
National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 2007 Apr
20; 25 (12) 1553 – 1561.
11. Shepherd FA, Rosell R. Weighing Tumour biology in Treatment Decisions for Patients
with Non-Small Cell Lung Cancer. Supp J Thor Oncol 2007 Jun: 2 (6): S68 – S76
12. Rodin G, Walsh A, Zimmermann C, Gagliese L, Jonnes J, Shepherd FA, Moore M,
Braun M, Donner A, Mikulincer M. The contribution of attachment security and social
support to depressive symptoms in patients with metastatic cancer. Psychooncology.
2007; 12: 1080-91.
13. Rodin G, Zimmerman C, Rydall A, Jones J, Shepherd FA, Moore M, Fruh M, Donner
A, Gagliese L. The desire for Hastened Death in Patients with Metastatic Cancer. J Pain
Symptom Manage. 2007 Jun; 33 (6): 661-675.
14. Ng R, Hasan B, Mittman N, Florescu M, Shepherd FA, Ding K, Butts CA, Cormier Y,
Darling G, Goss GD, Inculet R, Seymour L, Winton T, Evans WK, Leighl NB; Working
Group on Economic Analysis; Lung Disease Site Group; National Cancer Institute of
Canada Clinical Trials Group. Economic Analysis of NCIC CTG JBR.10: a randomized
6

trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage nonsmall
cell lung cancer - a report of the Working Group on Economic Analysis, and the
Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. J
Clin Oncol. 2007 Jun 1; 25 (16): 2256-61.
15. Bradbury PA, Shepherd FA. Chemotherapy and surgery for operable NSCLC. Lancet.
2007; 369: 1903-4.
16. Corson TW, Zhu CQ, Lau SK, Shepherd FA, Tsao MS, Gallie BL. KIF14 Messenger
RNA Expression is Independently Prognostic for Outcome in Lung Cancer. Clin Cancer
Res. 2007 Jun 1;13 (11): 3229-34.
17. Tsao MS, Liu G, Shepherd FA. Serum Proteomic classifier for predicting response to
epidermal growth factor receptor inhibitor therapy: have we built a better mousetrap?
J Natl Cancer Inst. 2007 Jun 6; 99 (11): 826-7.
18. Laurie S, Ding K, Whitehead M, Feld R, Murray N, Shepherd FA, Seymour L. The
impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a
combined analysis of studies of the National Cancer Institute of Canada Clinical trials
Group. Ann Oncol. 2007 Jun; 18 (6): 1051-5.
19. Uy KL, Darling G, Xu W, Yi QL, De Perrot M, Pierre AF, Waddell TK, Johnston MR,
Bezjak A, Shepherd FA, Keshavjee S. Improved Results of induction chemoradiation
before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung
cancer. J Thorac Cardiovasc Surg. 2007 Jul; 134 (1): 188-93.
20. Arnold A, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M,
Whitehead M, Ellis P, Goss G, Chan A, Shepherd FA. Phase II study of vandetanib or
placebo in small cell lung cancer patients after complete or partial response to
chemotherapy plus or minus radiation. J Clin Oncol 25: 4278-84, 2007.
21. Pisters K, Evans WK, Azzoli CG, Kris MG, Smith CA, Somerfield MR, Shepherd FA.
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy
and adjuvant radiation therapy for stages I-IIIA respectable non-small cell lung cancer. J
Clin Oncol 25: 5506-18, 2007
22. Weir BA, Woo MS, Getz G, Perner S, Ding Li et al, Shepherd FA, et al, Meyerson M.
Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-8, 2007.
23. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Shepherd FA., et al. Prognostic and predictive
importance of p53 and RAS for adjuvant chemotherapy in non-small cell lung cancer. J
Clin Oncol. 25: 5240-7, 2007.
24. Lau SK, Boutros PC, Pintile M, Shepherd FA, et al. Three-gene prognostic classifier for
early-stage non-small cell lung cancer. J Clin Oncol. 25: 5562-9, 2007.
25. Butts CA, Bodkin D, Middleman EL, et al. Shepherd FA. Randomized phase II study of
gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients
with advanced or metastatic non-small cell lung cancer. J Clin Oncol. 25: 5777-84, 2007.
26. Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky L, Shaikh Z,
Goldstraw P. The International Association for the Study of Lung Cancer lung cancer
staging project: proposals regarding the clinical staging of small cell lung cancer in the
forthcoming (seventh) edition of the tumour, node, metastasis classification for lung
cancer. J Thorac Oncol 2007; 26:1067-77
27. Roberts HC, Patsios D, Paul NS, McGregor M, et al, Shepherd FA. Lung cancer
screening with low-dose computed tomography: Canadian experience. Can Assoc Radiol
J. 58: 225-35, 2007.
28. Asmis TR, Ding K, Seymour L, Shepherd FA, et al. Age and comorbidity as
independent prognostic factors in the treatment of non-small cell lung cancer: a review of
National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 26: 54-9,
2008.
7

29. Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, et al, Shepherd FA,
Christiani DC, Liu G. A rapid outcomes ascertainment system improves the quality of
prognostic and pharmacogenic outcomes fromobservational studies. Cancer Epidemiol
Biomarkers Prev.: 17(1): 204-11. Jan 2008.
30. Fruh M, Zhou W, Zhai R, Su L, Heist RS, Lynch, TJ, Shepherd FA, Christiani DL, Liu
G. Polymorphisms of inflammatory and metalloproteinase genes, Helicobacter pylori
infection and the risk of eosophageal adenocarcinoma. Cancer Epidermal 2008; 98: 689-
92.
31. Wakelee H, Langer C,Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Shepherd FA, Choy
H, Gandara DR. Cooperative group research efforts in lung cancer: focus on early-stage
non-small cell lung cancer. Clin Lung Cancer 9: 9-15, 2008.
32. Wheatley-Price P, Shepherd FA. Epidermal growth factor receptor inhibitors in the
treatment of lung cancer: reality and hopes. Curr Opin Oncol. 2: 162-75, 2008.
33. Gridelli C, Ardizzoni A. Ciardiello F, Shepherd FA, et al. Second-line treatment of
advanced non-small cell lung cancer. J Thorac Onc 3: 430-40, 2008
34. Laurie SA, Gouthier I, Arnold A, Shepherd FA, et al Seymour L. Phase I and
pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial
growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients
with advanced non-small-cell lung cancer: the National Cancer Institute of Canada
clinical trials group. J Clin Oncol. 26: 1871-8, 2008
35. Langer CJ, Wakelee H, Schiller J, Choy H, Shepherd FA, Vokes EE, Adjei AA, Baas P,
Saijo N, Gandara DR. Cooperative group portfolio in locally advanced non-small cell
lung cancer: are we making progress? Clin Lung Cancer; 9 (2): 85-91 Mar 2008.
36. Lee CW, Martin J, MacRae R, Tsao MS, Nguyen E, Johnston M, Baas P, Laurie S, Feld
R, Murrya N, Shepherd FA. Malignant mesothelioma: Canadian perspective and
research directions. Current Oncology 152: 104 – 111, 2008.
37. Wheatley-Price P, Ding K, Seymopur L, Clark GM, Shepherd FA. Erlotinib for
advanced non-small cell lung cancer in the elderly: an analysis of the National Cancer
Institute of Canada Clinical Trials Grooup Study BR.21. J Clin Oncol. 26(14): 1250-7.
May 2008.
38. Shepherd FA. Molecular selection of patients for first-line treatment of advanced nonsmall
cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime
time. J. Clin Oncol. 20: (15): 2426-7 May 2008.
39. Sakurada A, Lara-Guerra H, Liu N, Shepherd FA, Tsao MS. Tissue heterogeneity of
EGFR mutation in lung adenocarcinoma. J Thorac Oncol: 3 (5): 527-9. 2008.
40. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, et al., Chevalier T.
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative
Group. J Clin. Oncol. 2008; 26: 2552-9.
41. Leighl NB, Shepherd FA, Zawisca D, Burkes RL, Feld R, Waldron J, Sun A, Payne D,
Bezjak A. Enhancing treatment decision-making: pilot study of a treatment decision aid
in stage IV non-small cell lung cancer. Br J Cancer. 98(11): 1769-73. May 2008.
42. Florescu M, Hasan B, Seymour L, Ding K, Shepherd FA. A clinical prognostic index for
patients treated with erlotinib in National Cancer Institute of Canada Clinical Trial Group
study BR.21. J Thorac Oncol. 3(6): 590-8. Jun 2008.
43. Lynch TJ, Blumenschein GR Jr, Engelman JA, et al. Shepherd FA, Socinski M,
Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the
treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for
combination therapy. J Thorac Oncol. 3 (6 suppl 2): S107-12. Hun 2008.
44. Bradbury PA, Shepherd FA. Immunotherapy for lung cancer. J Thorac Oncol. 3 (6 suppl
2): S164-70.
8

45. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P; International Staging
Committee including Shepherd FA, and Participating Institutions. The impact of
additional prognostic factors on survival and their relationship with the anatomical extent
of disease expressed by the 6 th edition of the TNM Classification of Malignant Tumors
and the proposals for the 7 th edition. J Thorac Oncol. 2008 May; 3:457-66.
46. Zhu CQ, da cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P,
Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS, National
Cancer Institute of Canada Clinical Trials Group Study BR.21. Role of KRAS and EGFR
as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical
trials Group Study BR.21. J Clin Oncol. 2008 Sep 10: 26:4268-75.
47. Fruh M, Rolland E, Pignon JP, Seymour L, Ding K, Tribodet H, Winton T, le Chevalier
T, Scaliotti GV, Douillard JY, Spiro S, Shepherd FA. Pooled analysis of the effect of
age on adjuvant cisplatin-based chemotherapy for completely resected non-small cell
lung cancer. J Clin Oncol. 2008; 26: 3573-81
48. Director’s Challenge Consortium for the Molecular Classification of Lung
Adenocarcinoma, Shedden K, Taylor JM, Enkemann SA, Tsao MS, Jurisica I, Zhu CQ,
Strumpf D, Shepherd FA, Ding K, Seymour L, Rusch K, Meyerson M, Dobbin KK,
Lively T, Jacobson JW, Beer DG. Gene expression-based survival prediction in lung
adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008 Aug: 14: 822-7.
49. Bezjak A, Lee CW, Ding K, Brundage M, Winton T, Graham B, Whitehead M, Johnson
DH, Livingston RB, Seymour L, Shepherd FA. Quality-of-life outcomes for adjuvant
chemotherapy in early-stage non-small cell lung cancer. J Clin Oncol. 2008 Nov 1; 26:
5052-9.
50. Wheatley-Price P, Shepherd FA. Targeting angiogenesis in the treatment of lung cancer.
J Thorac Oncol. 2008; 3: 1173-84.
51. Travis WD, Giroux DJ, Chansky K, Crowley J, Asamura H, Brambilla E, Jett J, Kennedy
C, Rami-Porta R, Rusch VW, Goldstraw P, International Staging Committee including
Shepherd FA and Participating Institutions. The IASLC Staging Project: poposals for the
inclusion of broncho-pulmonary carcinoid tumors in forthcoming (seventh) edition of the
TNM Classification for Lung Cancer. J Thorac Oncol. 2008 Nov; 3: 1213-23.
52. McKay JD, Hung RJ, Gaborieau V, Shepherd FA, Field J, Lathrop M, Brennan P. Lung
cancer susceptibility locus at 5p15.33. Nat Genet. 2008 Dec: 40: 1404-6.
53. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers,
Shepherd FA, Lippman SM, Douillard JY et al. Gefitinib versus docetaxel in previously
treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet. 2008;
372:1809-18.
54. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, Leighl NB, Shepherd FA,
Powers J, Seymour L, Laurie SA. Tumor cavitation; impact on objective response evaluation
in trials of angiogenesis inhibitors in non-small cell lung cancer. J Clin Oncol. 2009; 27: 404-
10.
55. Goss G, Shepherd FA, Laurie S, Gauthier I, Leighl N, Chen E, Feld R, Powers J, Seymour L.
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular
endothelial growth factor tyrosine kinases, in combomation with cisplatin and gemcitabine in
patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of
Canada Clinical Trials Group. Eur J Cancer. 2009; 45: 782-8
56. Ellis J, Lin J, Walsh A, Lo C, Shepherd FA, Moore M, Li M, Gagliese L, Zimmerman C,
Rodin G. Predictors of referral for specialized psychosocial oncology care in patients with
metastatic cancer; the contributions of age, distress, and marital status. J Clin Oncol. 2009 Feb
10; 27: 699-705..
57. Al Husaini H, Wheatley-Price P, Clemons M, Shepherd FA. Prevention and management of
bone metastases in lung cancer: a review. J Thorac Oncol. 2009 Feb; 4: 251-9.
9

58. Anraku M, Waddell TK, de Perrot M, Lweis SJ, Pierre AF, Darling GE, Johnston MR, Zener
RE, Rampersaud YR, Shepherd FA, Leighl N, Bezjak A, Sun AY, Hwang DM, Tsao MS,
Keshavjee S. Induction chemoradiotherapy facilitates radical resection of T4 non-small cell
lung cancer invading the spine. J Thorac Oncol. 2009 Feb; 137: 441-447.
59. Boutros PC, Lau Sk, Pintilie M, Liu N, Shepherd FA, Der SD, Tsao MS, Penn LZ, Jurisica I.
Prognostic gene signatures for non-small cell lung cancer. Proc Natl Acad Sci U S A. 2009
Feb 5.
60. Ellis PM, Morzycki W, Melosky B, Butts C, Hirsh V, Krasnoshtein F, Murray N, Shepherd
FA, Soulieres D, Tsao MS, Goss G. The role of the epidermal growth factor receptor tyrosine
kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small cell lung cancer:
a Canadian national consensus statement. Curr Onc. 2009 16: 25-46.
61. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd
FA. The differential efficacy of pemetrexex according to NSCLC histology: a review of two
phase III studies. Oncologist 2009 Mar 14: 253-63.
62. Gauthier LR, Rodin G, Zimmerman C, Warr D, Moore M, Shepherd FA, Gagliese L.
Acceptance of pain: a study in patients with advanced cancer. Pain 2009 May 143: 147-54.
63. Le Maitre A, Ding K, Shepherd FA, Leighl N, Arnold A, Seymour L, NCIC Clinical trials
Group. Anticoagulation and bleeding; a pooled analysis of lung cancer trials of the NCIC
Clinical Trials Group. J Thoracic Oncol. 2009 May: 4: 586-94.
64. Roberts HC, Patsios DA, Paul NS, dePerrot M, Teel W, Bayanati H, Shepherd FA, Johnston
MR. Screening for malignant pleural mesothelioma and lung cancer in individuals with a
history of asbestos exposure. J Thoracic Cardiovascular Surg, 2009 Oct 138:843-8.
65. Menezes RJ, Roberts HC, Paul NS, McGregor M, Chung TB, Patsios D, Weisbrod G, Herman
S, Pereira A, McGregor A, Dong Z, Sitartchuk I, Boerner S, Tsao MS, Keshavjee S,
Shepherd FA. Lung cancer screening using low-dose computed tomography in at-risk
individualsL The Toronto experience. Lung Cancer 2009; 67,177-83.
66. Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, Capuzzo F, Sharma S,
Gross Sh, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulo V. Efficacy
of everolimus (RAD001) in patients with advanced NSCLC previously treated with
chemotherapy and EGFR inhibitors. Ann Oncol. 2009 Oct 20: 1674-81.
67. Bradbury PA, Kulke MH, Heist RS, Zhou W, Ma C, Xu W, Marshall Al, Zhai R, Hooshmand
SM, Asomaning K, Su L, Shepherd FA, Lynch TJ, Wain JC, Christiani DC, Liu G. Cisplatin
pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.
Pharmacogenet Genomics. 2009 Aug: 613-25.
68. Wheatley-Price P, Massey C, Panzarella T, Shepherd FA, Mikhael J. Resident preparedness in
discussing prognosis in patients with advanced lung cancer. Support Care Cancer. 2009 Jul 21.
69. Albain KS, Swann RS, Rush VW, Turrisi AT 3 rd , Shepherd FA, Smith C, Chen Y, Livingston
RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J,
Sause WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection die stage
III non-small cell lung cancer: a phase III randomized controlled trial. Lancet 2009 Aug 1: 379-
86.
70. Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, Chiappori A, Halmos B, Favis R, Liu
H, Trepicchio WL, Eton O, Shepherd FA. A randomized phase 2 study of erlotinib alone and in
combination with bortezomib in previously treated advanced non-small cell lung cancer. J
Thoracic Oncol. 2009 Aug 4: 1002-9.
71. Vallieres E, Shepherd FA, Crowley J, Van Houtte P. Postmus PE, Carney D, Chansky K, Shaikh
Z, Goldstraw P, International Association for the Study of Lung Cancer international Staging
Committee and Participating Institutions. The IASLc Cancer Staging Project: proposals regarding
the revelance of TNM in the pathologic staging of non-small cell lung cancer in the forthcoming
(seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009 Sep 4: 1049-
59.
10

72. Patel A, Anraku M, Darling GE, Shepherd FA, Pierre Af, Waddell TK, Keshavjee S, de perrot
M. Venous thromboembolism in patients receiving multimodality therapy for thoracic
malignancies. J Thorac Cardiovasc Surg. 2009 Oct 138: 843-8.
73. Jang RW, Le Maitre A, Ding K, Winton T, Bezkjak A, Seymour L, Shepherd FA, Leighl NB.
Quality-adjusted time without symptoms of toxicity analysis of adjuvant chemotherapy in nonsmall
cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials
Group JBR.10 trial. J Clin Oncol. 2009; 27: 4268-73.
74. Leighl NB, Laurie SA, Chen XE, Ellis P, Shepherd FA, Knox JJ, Goss G, Burkes RL, pond GR,
Dick C, Yen Y, Zwiebel JA, moore MJ. A phase I/II study of GTI-2040 plus docetaxel as secondline
treatment in advanced non-small cell lung cancer; a study of the PMH phase II consortium. J
Thorac Oncol. 2009 Sep 4: 1163-9.
75. Hicks LK, Cheung MC, Ding K, Hasan B, Seymour L, Le Maitre A, Leighl NB, Shepherd FA.
Venous thromboembolism and non-small c ell lung cancer: a pooled analysis of the National
Cancer Institute if Canada clinical trials Group trials.Cancer. 2009 Dec 1: 5516-25.
76. Coate LE, John T, Taso MS, Shepherd FA. Molecular predictive and prognostic markers in nonsmall
cell lung cancer. Lancet Oncol. 2009 Oct 10: 1001-10.
77. Zhu CQ, Pintille M, John T, Strumpf D, Shepherd FA, Der SD, Jurisica I, Tsao MS.
Understanding prognostic gene expression signatures in lung cancer. Clin Lung Cancer. 2009;
10: 331-40.
78. Lara-Guerra H, Waddell TK, Salvarrey MA, Joshua AM, Chung CT, Paul N, Boerner S, Sakurada A,
Ludkovski O, Ma C, Squire J, Liu G, Shepherd FA, Taso MS, Leighl NB. Phase II Study of
Perioperative Gefitinib in Clinical Stage I Non-Small Cell Lung Cancer. J Clin Oncol. 2009; 27:
6229-36
79. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D,
Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C,
Noble J, Lee CW, Seymour L. Randomized, Double-blind trial of Carboplatin abd Paclitaxel With
Either Daily Oral Cediranib or Placebo in Advanced Non-Small Cell Lung Cancer: NCIC Clinical
trials Group BR.24 Study. J Clin Oncol. 2010; 28: 49-55.
80. Douillard JY, Shepherd FA, Hirsch V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H,
Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES. Molecular Predictors of
Outcome with gefitinib and docetaxel in Previously Treated Non-Small Cell Lung Cancer: Data
from the Randomized Phase III INTEREST Trial. J Clin Oncol. 2010; 28: 44-52.
81. Douillard JY, Tribodet H, Aubert D, Shepherd FA, Rosell R, Ding K, Veillard AS, Seymour L,
Le Chevalier T, Spiro S, Stephens R, Pignon JP, LACE Collaborative Group. Adjuvant cisplatin
and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of Lung
Adjuvant Cisplatin Evaluation. J Thoracic Oncol. 2010; 5: 220-8.
82. Wheatley-Price P, Ma C, Ashcroft LF, Nankivell M, Stephens RJ, White SC, Lorigan P, Thatcher
N, Blackhall FH, Shepherd FA. The Strength of female sex as a prognostic factor in small-cell
lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and
medical research Council Clinical Trials Unit. Ann Oncol. 2010; 21: 232-7.
83. Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittman N, Tsao MS, Evans WK,
Shepherd FA, Leighl NB, NCIC Clinical Trials Group Working Group on Economic Analysis.
Economic Analysis: randomized placebo-controlled clinical trials of erlotinib in advanced nonsmall
cell lung cancer. J Natl Cancer Inst. 2010; 102: 298-306.
84. Ross HJ, Blumenschein GR Jr, Aisner J, Damjanov N, Dowlati A, Garst J, rigas JR, Smylie M,
Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA. Randomized phase II multicenter trial
of two schedules of lapatinib as first or second-line monotherapy in patients with advanced or
metastatic non-small cell lung cancer. Clin Cancer Res 2010; 16: 1938-49.
85. Wheatley-Price P, Blackhall F, Lee SM, Ma C, Ashcroft L Jitlal M, Qian W, Hackshaw A, Rudd
R, Booton R, Danson S, Lorigan P, Thatcher N, Shepherd FA. The influence of sex and
11

histology on outcomes in non-small cell lung cancer: a pooled analysis if five randomized trials.
Ann Oncol. 2010; 10: 2023-8.
86. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P
Intenational Staging Committee including Shepherd FA, and Participating Institutions.
The International Association for the Study of Lung Cancer Staging Project. Zhongguo
Fei Ai Za Zhi. J Thorac Oncol 2010; 13: 9-18.
87. NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, Burdett S, Higgins JP,
Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, Souhami RL, Stephens RJ,
Stewart LA, Tierney JF, Tribodet H, Shepherd FA, van Meerbeeck J. Adjuvant chemotherapy,
with or without postoperative radiotheraopy, in operable non-small cell lung cancer: two metaanalyses
of individual patient date. Lancet. 2010; 375: 1267-77.
88. Goodwin R, Ding K, Seymour L, LeMaitre A, Arnold A, Shepherd FA, Dediu M, Ciuleanu T,
Fenton D, Zukin M, Walde D, Laberge F, Vincent M, Ellis PM, Laurie SA, NCIC Clinical Trials
Group Study BR.24. Group. Ann Oncol. 2010; 21: 2220-07.
89. Wheatley-Price P, Le Maitre A, Ding K, Leighl N, Hirsh V, Seymour L, Bezjak A, Shepherd
FA. The influence of sex on efficacy, adverse events, quality of life and delivery of treatment in
NCIC Clinical Trials Group non-small cell lung cancer chemotherapy trials. J Thorac Onc. 2010;
5: 640-8.
90. Gridelli C, Ardizzoni A, Douillard JY, Hanna N, Manegold C, Perrone F, Pirker R, Rosell R,
Shepherd FA, De Petris L, Di Maio M, de Marinis F. Recent issues in first-line treatment of
advanced non-small cell lung cancer: Results of an International Expert Panel Meeting of the
Italian Association of Thoracic Oncology. Lung Cancer. 2010; 68: 319-31
91. Lo C, Zimmerman C, Rydall A, Walsh A, Jones JM, Moore MJ, Shepherd FA, Gagliese L,
Rodin G. Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal
and lung cancer. J Clin Oncol. 2010; 28: 3084-9.
92. Brenner DR, Hung RJ, Tsao MS, Shepherd FA, Johnston MR, Narod S, Rubenstein W,
McLaughlin JR. Lung cancer risk in never-smokers: a population-based-case-control study of
epidemiologic risk factors. BMC Cancer 2010; 10: 285.
93. Booth CM, Shepherd FA, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ. Adoption of
adjuvant chemotherapy for non-small cell lung cancer: a population-based outcomes study. J Clin
Oncol. 2010 20; 28: 3472-8.
94. Leighl NB, Raez LE. Besse B, rosen PJ, Barlesi F, Massarelli E, Gabrail N, Hart LL, Albain KS,
Berkowitz L, Melnyk O, Shepherd FA, Sternas L, Ackerman J, Shun Z, Miller VA, Herbst RS. A
multicenter, phase 2 study of vascular endothelial growth factor trap (afibercept) in platinum- and
erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol. 2010; 5: 1054-9.
95. Shepherd FA, Mallarkey G. Highlights of the 2 nd Eurpoean Lung Cancer Conference. Editorial:
Therapeutic Advances in Med Oncol 2010; 2: 297-299.
96. Wei Y, Tong J, Taylor P, Strumpf D, Ignatchenko V, Pham NA, Yanagawa N, Liu G, Jurisica I,
Shepherd FA, Tsao MS, Kislinger T, Moran MF. Primary Tumor Xenografts of Human Lung
Adeno and Squamous Cell Carcinoma Express Distinct Proteomic Signatures. J Proteome Res. 2010;
10: 161-74
97. Giuliani M, Sun A, Bezjak A, Ma C, Le LW, Brade A, Cho J, Leighl NB, Shepherd FA, Hope AJ.
Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma.
Cancer. 2010; 116: 5694-6.
98. Zhu CQ, Strumpf D, Li CY, Li Q, Liu N, Der S, Shepherd FA, Tsao MS, Jurisica I. prognostic gene
expression signature for squamous cell carcinoma of the lung. Clin Cancer Res. 2010; 16: 5038-47.
99. Brade A, Bezjak A, Macrae R, Laurie S, Sun A, Cho J, Leighl N, Pearson S, Southwood B, Wang L,
McGill S, Iscoe N, Shepherd FA. Phase I Trial of Radiation with Concurrent and Consolidation
Pemetrexed and Cisplatin in Patients with Unresectable Stage IIIA/B Non-Small Cell Lung Cancer.
Int J Radiat Oncol Bio Phys. 2010; 79: 1395-401.
12

100. Jang RW, Isogai PK, Mittmann N, Bradbury PA, Shepherd FA, Feld R, Leighl NB.
Derivation of utility values from European Organization for Research and Treatment of Cancer
Quality of Life-Core 30 questionnaire values in lung cancer. J Thorac Oncol. 2010; 12: 1953-7.
101. John T, Kohler D, Pintilie M, Yanagawa N, Pham NA, Li M, Panchal D, Hui F, Meng F,
Shepherd FA, Tsao MS. The Ability to Form Primary Tumour Xenografts is Predictive of Increased
Risk of Disease Recurrance in Early Stage Non-small Cell Lung Cancer. Clin Cancer Res. 2011; 17:
134-41.
102. Addison CL, Ding K, Zhao H, Le Maitre A, Goss GD, Seymour L, Tsao MS, Shepherd FA,
Bradbury PA. Plasma Transforming Growth Factor alpha and Amphiregulin Protein Levels in NCIC
Clinical Trials Group BR.21. J Clin Oncol. 2010; 28: 5247-56.
103. Boutros PC, Pintilie M, John T, Starmans MH, Der SD, Shepherd FA, Tsao MS, Jurisica I.
Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer
Inst. 2010; 102: 1677-8.
104. Da Cunha Santos G, Shepherd FA. EGFR Mutations and Lung Cancer. Annu Rev Pathol.
2010; 6: 49-69.
105. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K,
Ladd-Acosta C, Liu N, Pintilie M, Der S, Seymour L, Jurisica I, Shepherd FA, Tsao MS. Prognostic
and predictive gene signature for adjuvant chemotherapy in resected non-small cell lung cancer. J
Clin Oncol. 2010; 28: 4417-24.
106. Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Goss G, et al, Shepherd FA.
Randomized Phase III trial of vinorelbione and ciaplatin compared with observation in completely
resected stage IB and II non-small cell lung cancer: updated survival analysis of JBR.10. J Clin Oncol
2010; 28: 29-34.
107. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, et al. Randomized
double blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in
advanced non-small cell lung cancer. J Clin Oncol 2010; 28: 49-55.
108. Pallis AG, Shepherd FA, Lacombe D, Gridelli C. Treatment of small-cell lung cancer in
elderly patients. Cancer. 2010; 116: 1192-200.
109. Coate LE, Shepherd FA. Maintenance therapy in advanced non-small cell lung cancer. J
Thorac Oncol. 2010; 5: 723-34.
110. Fruh M, Shepherd FA. Adjuvant cisplatin-based chemotherapy for elderly paitents with
completely resected non-small cell lung cancer: Review of current evidence. Eur J Cancer, Med
Oncol 2010; 2: 59-63.
111. Shepherd FA. Surgery for limited stage small cell lung cancer: time to fish or cut bait. J
Thorac Oncol. 2010; 5: 147-9.
112. Shepherd FA, Tsao MS. Epidermal growth factor receptor biomarkers in non-small-cell lung
cancer: a riddle, wrapped in a mystery, inside an enigma. J Clin Oncol. 2010; 28: 903-5.
113. Vansteenkiste JF, Shepherd FA. The seventh tumor, node, metastases staging system and
lung cancer treatment choices: a matter of would, could, and should. J Thoracic Onc. 2010; 11:
1724-5.
114. Shepherd FA, Maintenance therapy comes of age for non-small-cell lung cancer, but at
what cost? J Clin Oncol 2011; 29: 4068-70.
115. Vallieres E. Vanhoutte P, Travis WD, Rami-Porta R, Goldstraw P, Shepherd FA,
International Association for the Study of Lung Cancer (IASLC) International Staging Committee.
Carcinoma in-situ at the bronchial resection margin: a review. J. Thorac Oncol. 2011; 6: 1617-23.
116. Coate LE, Shepherd FA, Maintenance therapy in advanced non-small cell lung
cancer: evolution, tolerability and outcomes. Ther Avd Med Oncol 2011; 3: 139-57.
117. Shepherd FA, Douillard JY, Blumenschein GR Jr. Immunotherapy for nonsmall
cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol.
2011; 10: 1763-73.
13

118. Giuliani ME, Atallah S, Sun A. Bezjak A, Le LW, Brade A, Co J, Leighl NB,
Tsao MS, Leighl NB, Shepherd FA, Hope AJ, Clinical outcomes of extensive stage
small cell lung carcinoma patients treated with consolidative thoracic radiotherapy, Clin
Lung Cancer. 2011; 12: 375-9 .
119. Ellis PM, Blais N, Soulieres D, lonescu DN, Kashyap M, Liu G, Melosky B,
Reiman T, Romeo P, Shepherd FA, Tsao MS, Leighl NB. A systematic review and
Canadian concensus recommendations on the use of biomarkers in the treatment of nonsmall
cell lung cancer. J Thorac Oncol 2011; 8: 1379-91
120. Shepherd FA. Molecular selection trumps clinical selection. J Clin Oncol.
2011; 29: 2843-4
121. Cuffe S, Moua T. Summerfield R, Roberts H, Jett J, Shepherd FA.
Characteristics and outcomes of small cell lung cancer patients diagnosed during two
lung cancer computed tomographic screening programs in heavy smokers. J Thorac
Oncol. 2011; 6: 818-22
122. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E. Nicholson AG, Shepherd
FA. Non-small-cell lung cancer. Lancet. 2011; 378: 1727-40
123. Liu G, Gramling S, Munoz D, Cheng D, Azad AK, Mirshams M, ChenZ, Xu W,
Roberts H, Shepherd FA, Tsao MS, Reisman D. Two novel BRM insertion promoter
sequence variants are associated with loss of BRM expression and lung cancer risk.
Oncogene, 2011; 30: 3295-304
124. Navab R, Strumpf D, Bandarchi B, Zhu CQ, Pintilie M, Ramnarine VR,
Ibrahimov E, Radulovich N Leung L, Barczyk M, Panchal D, To C, Yun JJ, Der S,
Shepherd FA, Jurisica I, Tsao MS. Prognostic gene-expression signature of carcinomaassociated
fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U.S.A. 2011;
108: 7160-5
125. Horgan AM, Bradbury PA, Amir E. Ng R, Douillard JY, Kim ES, Shepherd FA,
Leighl NB. An economic analysis of the INTEREST trial, a randomized trial of
docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell
cancer. Ann Oncol 2011; 8: 1805-11
126. Lara PN Jr, Longmate J, Reckamp K, Gititz B, Argiris A, Ramalingam S, Belani
CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR.
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in
advanced non-small cell lung cancer: a California cancer consortium trial. Clin Lung
Cancer 2011; 12: 33-7
127. John T, Kohler D, Pintilie M, Yanagawa N, Pham NA, Li M, Panchal D, Hui F,
Meng F, Shepherd FA, Tsao MS. The Ability to Form Primary Tumour Xenografts is
Predictive of Increased Risk of Disease Recurrance in Early Stage Non- small Cell Lung
Cancer. Clin Cancer Res. 2011; 17: 134-41.
128. Jang RW, Isogai PK, Mittmann N, Bradbury PA, Shepherd FA, Feld R, Leighl
NB. Derivation of utility values from European Organization for Research and
Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer. J
Thorac Oncol. 2010; 5: 1953-7.
129. Coate LE, Massey C, Hope A, Sacher A, Barrett K, Pierre A, Leighl N, Brade A,
de Perrot M, Waddell T, Liu G, Feld R, Burkes R, Cho BC, Darling G, Sun A. Keshavjee
S, Bezjak, Shepherd FA. Treatment of the elderly when cure is the goal: the influence
of age on treatment selection and efficacy for stage III non-small cell lung cancer. J
Thorac Oncol. 2011; 6: 537-44.
130. Wei Y, Tong J, Taylor P, Strumpf D, et al, Jurisica I, Shepherd FA, Tsao MS,
Kislinger T, Moran MF. Primary tumour xenografts of of human lung adenocarcinoma
and squamous cell carcinoma express distinct proteomic signatures. J Proteome Res
2011; 10: 161-74.
14

131. Horgan AM, Yang B, Azad AK, Amir E, John T, Cescon DW, Wheatley-Price P, Hung
RJ, Shepherd FA, Liu G. Pharmacogenetic and germline prognostic markers of lung
cancer. J Thorac Oncol. 2011; 6: 296-304.
132. Tsao Ms, Sakurada A, Ding K, Aviel-Ronen S, Ludkovski O, Liu N, Le Maitre A,
Gandara D, Johnson DH, Rigas JR, Seymour L, Shepherd FA. Prognostic and
predictive value of epidermal growth factor receptor tyrosine kinase domain mutuation
status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.
J Thorac Oncol. 2011; 6: 139-47.
133. Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, van Seenkiste J, et al. Treatment
by histology interaction analyses in three phase III trails show superiority of pemetrexed
in non-squamous non-small cell lung cacner. J Thorac Oncol 2011; 6: 64-70.
134. Reiman T, Lai R, Veillard AS, Psaris E. Sora JC, Rosell R, Taron M, Graziano S,
Kratzke R, Seymour L, Shepherd FA, Pignon JP, Seve P for the LACE-Bio Group.
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from
adjuvant chemotherapy in resected non-small cell lung cancer: analysis of four
randomized trials. Ann Oncol. 2012; 23: 86-93.
135. Brade A, Bezjak A, MacRae R, Laurie S, Sun A, Cho J, Leighl N, Pearson S,
Southwood B, Wang L, Mcgill S, Iscoe N, Shepherd FA. Phase I trial of radiation with
concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage
III/a/B non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011; 79: 1395-40.
136. Navaratnum S, Skliris G, Qing G, Banerji S, Badiani K, Bradbury PA, Leighl NB,
Shepherd FA, et al. Differential role of estrogen receptor beta in early versus metastatic
non-small cell lung cancer. Horm Cancer 2012;
137. Giuliani ME, Lindsay PE, Sun A, Bezjak A, Le LW, Brade A, Cho J, Leighl NB,
Shepherd FA, Hope AJ. Locoregional failures following thoracic irrradiation in patients
with limited stage small-cell lung cancer. Radiother Oncol 2102;
138. Liu G, Cheng D, Ding K, Le Maitre A, Liu N, Patel D, Chen Z, Seymour L, Shepherd
FA, Tsao MS. Pharmacogenetic analysis of BR.21, a placebo-controlled randomized
Phase III clinical trial of erlotinib in advanced non-small cell lung cancer. J Thorac
Oncol 2012;
12. BOOK CHAPTERS LAST 5 YEARS OUT OF A TOTAL OF 44
1. Leighl N and Shepherd FA. Adjuvant chemotherapy for non-small cell lung cancer. In:
General Thoracic Surgery Seventh Edition: Shields TW, Locicero III J, Feins R (eds).
Lipincott Williams & Wilkins, Philadelphia 2008 In Press.
2. Ellis P and Shepherd FA. Second-line chemotherapy for non-small cell lung cancer. In:
Lung Cancer: Principles and Practice 4th Edition: Pass H, Mitchell J, Johnson D, Turrisi
D (eds). JB Lippincott, Philadelphia, 2008 In Press.
3. Leighl NB, Shepherd FA. Small Cell Lung Cancer. Pearson’s Thoracic & Esophageal
Surgery Third Edition Volume 1 Thoracic: Churchill Livingston Elsevier, 825 – 840,
2008.
4. Leighl NB, Shepherd FA. Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer.
General Thoracic Surgery Seventh Edition Volume 1 Lippincott Williams & Wilkins,
2009
5. Wheatley-Price P and Shepherd FA. Epidermal Growth Factor Receptor Inhibitors in the
Treatment of Non-Small Cell Lung Cancer. Humana Press. Stewart D Ed 2010; 205-226.
6. Wheatley-Price P, Shepherd FA. Lung Cancer Prevention, Management, and Emerging
Therapies. Humana Press 2010.
15

7. Ellis PM, Shepherd FA. Chemotherapy for Recurrent or Refractory advanced Non-Small
Cell Lung Cancer. Principles and Practice of Lung Cancer The Official Reference Text of
the IASLC, 4 th Edition. Lippincott Williams & Wilkins. 2010. 669-683.
8. Huang CH, Shepherd FA, Kelly K. Chemotherapy for Small cell Lung Cancer.
Principles and Practice of Lung Cancer, the Official Reference Text of the IASLC, 4 th
Edition. Lippincott Williams & Wilkins. 2010. 847-866
16

13. ABSTRACTS AND PAPERS PRESENTED AT SCIENTIFIC MEETINGS LAST 5
YEARS OUT OF A TOTAL OF 444:
1. Franks KN, Bezjak A, Pearson S, Cho BC, Payne D, Sun A, Waddell TK, Shepherd FA,
Keshavjee S. Stereotactic body radiotherapy (SBRT) and medical inoperability of early
stage non-small cell lung cancer. J Clin Oncol 24, 18S: 672s (Abstract #17074), 2006.
2. Shepherd FA. Adjuvant Chemotherapy for Non-Small Cell Lung Cancer. Presented at
the 18 th International Congress on Anti Cancer Treatment. Paris Feb 2007.
3. Douillard JY, Tribodet H, Rosell R, DeLena M, Shepherd FA. Adjuvant chemotherapy
with cisplatin-vinorelbine in totally resected non-small cell lung cancer: results of the
ANITA trial and confirmatory data from the Lung Adjuvant Cisplatin Evaluation
(LACE). Presented at the 18 th International Congress on Anti Cancer Treatment. Paris
Feb 2007.
4. Bradbury PA, Marshall AL, Kulke MH, Shepherd FA. Prognostic significance of
nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in
esophageal cancer. J Clin Oncol 25, 18S: 99s, 2007. Journal of Clin Onc 25, 18S.
Presented at ASCO 2007.
5. Arnold AM, Smylie M, Ding K, Shepherd FA. Randomized phase II study of
maintenance vandetanib (ZD6474) in small cell lung cancer (SCLC) patients who have a
complete or partial response to induction therapy: NCIC CTG BR.20. Journal of Clin
Onc 25, 18S. Presented at ASCO June 2007.
6. Butts CA, Bodkin D, Middleman AL, Shepherd FA. Gemcitabine/platinum alone or in
combination with cetuximab as first-libne treatment for advanced non-small celllung
cancer (NSCLC). Journal of Clin Onc 25, 18S. Presented at ASCO June 2007.
7. Fruh M, Tribodet H, Pignon J, Shepherd FA. A pooled analysis of the effect of age on
adjuvant cisplatin-based chemotherapy for completely resected non-small cell lung
cancer (NSCLC). Journal of Clin Onc 25, 18S. Presented at ASCO June 2007.
8. Shepherd FA, Ding K, Sakurada A, Da Cuhna Santos G, Updated molecular analyses of
exons 19 and 21 of the epidermal growth factor receptor (EGFR) gene and codons 12 and
13 of the KRAS gene in non-small celllung cancer (NSCLC) patients treated with
erlotinib in National Cancer Institute of Canada. Journal of Clin Onc 25, 18S. Presented
at ASCO June 2007.
9. Tsao MS, Aviel-Ronen S, Ding K, Shepherd FA. P53 protein over-expression but not
p53 gene mutation is a poor prognostic marker and a predictive marker for survival
benefit from adjuvant chemotherapy in non-small cell lung cancer (NSCLC) in the
JBR.10 Trial. Journal of Clin Onc 25, 18S. Presented at ASCO June 2007.
10. Bezjak A, Lee CW, Ding K, Winton T, Shepherd FA. Quality of life (QOL) impact of
adjuvant chemotherapy for early stage non-small cell lung cancer (NSCLC): final
analysis of JBR.10 randomized trial. Journal of Clin Onc 25, 18S. Presented at ASCO
June 2007.
11. Papadimitrakopoulou V, Soria JC, Douillard JY, Giaccone G, Shepherd FA. A phase II
study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced nonsmall
cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior
C and EGFR inhibitors (EGFR-I). Journal of Clin Onc 25, 18S. Presented at ASCO June
2007. Journal of Thor Onc 2, 8. Presented at the 12 th World Conference on Lung Cancer,
Seoul, Korea, Sept 2007.
17

12. Smylie M, Blumenschein GR, Dowlati A, Garst J, Shepherd FA. A phase II multicenter
trial comparing to schedules of lapatinib (LAP) as first or second line monotherapy in
subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either
bronchi alveolar carcinoma (BAC) of no smoking history. Journal of Clin Onc 25, 18S.
Presented at ASCO June 2007.
13. Goss GD, Laurie S, Shepherd FA, Leighl N, Chen E. IND.175: Phase I study of daily
oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in
combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small
cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group. Journal of Clin
Onc 25, 18S. Presented at ASCO June 2007.
14. Liu G, fruh M, Zhou W, Zhai R, Shepherd FA. Matrix metalloproteinase 2 (MMP2)
polymorphism, Helicobacter pylori (HP) infection and esophageal adenocarcinoma (EA)
risk. Journal of Clin Onc 25, 18S. Presented at ASCO June 2007.
15. Shepherd FA, Crowley J, Van Houtte P, Postmus P. Clinical staging of small cell lung
cancer: report of the International Association for the Study of Lung Cancer Staging
Initiative, Small Cell Lung Cancer Subcommittee. Journal of Thor Onc 2, 8. Presented at
the 12 th World Conference on Lung Cancer, Seoul, Korea, Sept 2007.
16. Lara-Guerra H, Leighl N, Salvarrey A, Shepherd FA, Tsao MS. Preoperative gefitinib in
clinical stage I NSCLC. Journal of Thor Onc 2, 8. Presented at the 12 th World Conference
on Lung Cancer, Seoul, Korea, Sept 2007.
17. Laurie S, Crabb S, Arnold A, Goss G, Shepherd FA, Seymour L. Implications of tumour
cavitation on response assessment in trials of Vascular Endothelial Growth Factor
Receptor (VEGFR) Inhibitors in combination with platinum-based chemotherapy for
advanced non-small cell lung cancer (NSCLC): An analysis of trials conducted by the
National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Journal of Thor
Onc 2, 8. Presented at the 12 th World Conference on Lung Cancer, Seoul, Korea, Sept
2007.
18. Lee C, Pater J, Martin J, MacRae R, Shepherd FA. A survey of Canadian practice in
management of malignant pleural mesothelioma (MPM). Journal of Thor Onc 2, 8.
Presented at the 12 th World Conference on Lung Cancer, Seoul, Korea, Sept 2007.
19. Brade AM, Bezjak A, MacRae R, Laurie S, Shepherd FA. A phase I/II study of
concurrent pemetrexed/cisplatin/radiation in stage IIIa/b non-small cell lung cancer.
Journal of Thor Onc 2, 8. Presented at the 12 th World Conference on Lung Cancer, Seoul,
Korea, Sept 2007.
20. Bradbury PA, Seymour L, Ng R, Mittmann N, Shepherd FA. An economic analysis of
the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21, a
randomized trial of erlotinib versus best supportive care after cisplatin based
chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal of Thor Onc 2,
8. Presented at the 12 th World Conference on Lung Cancer, Seoul, Korea, Sept 2007.
21. Bahleda R, Felip E, Herbst RS, Hanna NH, Laurie S, Shepherd FA, Armand JP,
Sweeney CJ, Calvo-Aller E, Soria JC. Phase I multicenter trial of BMS-690514: Safety,
pharmacokinetic profile, biological effects, and early clinical evaluation in patients with
advanced solid tumours and non-small cell lung cancer. Presented at ASCO June 2008.
22. Bradbury PA, Tu D, Seymour L, Mg r, Zhu L, Isogai PK, Mittman N, Evans WK,
Shepherd FA, Leighl N. Impact of clinical and molecular predictors of benefit from
erlotinib in advanced non-small cell lung cancer on cost-effectiveness. Presenteed at
ASCO June 2008.
18

23. Jang RW, LeMaitre A, Ding K, Winton TL, Bezjak A, Seymour L, Shepherd FA, Leighl
N. A Q-TwiST analysis of adjuvant chemotherapy in non-small cell lung cancer
(NSCLC) in the NCIC CTG JBR.10 trial. Presented at ASCO June 2008.
24. Tsao MS, Zhu C, Ding K, Strumpf D, PintileM, Meyerson M, Seymour L, Jurisica I,
Shepherd FA. A 15-gene expression signature prognostic for survival and predictive for
adjuvant chemotherapy benefit in JBR.10 patients. Presented at ASCO June 2008.
25. Brade AM, Bezjak A, MacRae R, Laurie SA, PondGR, Wang L, Dick C, Afinec A, Iscoe
N, Shepherd FA. A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation
(RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC). Presented at
ASCO June 2008.
26. Wheatley-Price P, LeMaitre A, Ding K, Leighl NB, Hirsch V, Seymour L, Shepherd FA.
The influence of sex on efficacy, toxicity and delivery of treatment in National Cancer
Institute of Canada Clinical Trials Group (NCIC CTG) non-small cell lung cancer
(NSCLC) chemotherapy trials. Presented at ASCO June 2008.
27. LeMaitre A, Ding K, Shepherd FA, Leighl NB, Arnold A, Seymour L. Anticoagulation
and bleeding: A pooled analysis of lung cancer trials of the National Cancer Institute of
Canada Clinical Trials Group. Presented at ASCO June 2008.
28. Horgan AM, Shepherd FA, Bradbury PA, Ng R, Leighl NB. Preliminary costconsequence
analysis in INTEREST trial, a randomized trial of docetaxel versus
gefitinibas 2 nd line therapy in advanced non-small cell lung cancer. Presented at ASCO
June 2008.
29. Vincent MD, Butts C, Seymour L, Ding K, Graham B, Twumasi-Ankrah P, Gandara D,
Schiller J, Green M, Shepherd FA. Updated survival analysis of JBR.10: A randomized
phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB
and II non-small cell lung cancer (NSCLC). Presented at ACO 2009.
30. Richardson F, Richardson K, Sennello G, Young D, Orlov S, Papal-Szekely Z, Keshavjee
S, Kim J, Cerfolio R, Shepherd FA. Biomarker analysis from completely resected
NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT). Presented at
ASCO 2009.
31. Goodwin RA, Seymour L, Ding K, Gouthier I, Le Maitre A, Frymire E. Arnold A,
Shepherd FA, Goss GD. Hypertension (HTN) in National Cancer Institute of Canada
Clincial Trials Group study BR.24: A randomized, double-blinded phase II trial of
carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of
vascular endothelial growth factor receptors, or placebo, in patients with advanced nonsmall
cell lung cancer. Presented at ASCO 2009.
32. Shepherd FA, Douillard J, Fukuoka M, Saijo N, Kim s, Cufer T, Sellers MV, Armour
AA, Kim ES. Comparison of gefitinib and docetaxel in patienst with pretreated advanced
non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. Presented at
ASCO 2009.
33. Bradbury PA, Twumasi-Ankrah P, Ding K, Leighl NB, Goss GD, Laurie S, Shepherd
FA, Seymour L. The impact of brain metastases on overall survival (OS) in National
Cancer Institute of Canada Clinical Trials Grooup(NCIC CTG) clinical trials (CT) in
advanced non-small cell lung cancer (NSCLC). Presented at ASCO 2009.
34. Bahleda R, Soria J, Harbison C, Park J, Felip E, Hanna N, Laurie SA, Armand J,
Shepherd FA. Tumor regression and pharmacodynamic (PD) biomarker validation in
non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor
BMS-690514. Presented at ASCO 2009.
35. Goss GD, Addison C, Shepherd FA, Seymour L. TGF-cx and amphiregulin levels in
non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib/placebo in
19

National cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21. Presented
at ASCO.
36. John T, Li M, Panchal D, Hui F, Meng F, Bandarchi-Chamkhaleh B, Kohler D, Zhu C,
Shepherd FA, Tsao M. Correlation of primary tumor engraftment in immune deficient
mice and relapse rate in patients with early-stage non-small cell lung carcinoma
(NSCLC). Presented at ASCO 2009.
37. Goss GD, Lorimer I, Tsao MS, O’Callaghan CJ, Ding K, Masters GA, Roberts P, Jett JR,
Edelman MJ, Shepherd FA. A phase III randomized, double-blind, placebo-controlled
trial of epidermal growth factor receptor inhibitor gefitinib in completely resected stage
IB-IIIA non-small cell lung cancer (NSCLC): NCIC BR.19. Presented at ASCO,
Chicago, IL June 2010 J Clin Oncol 28, 15S: 516s, 2010.
38. John T, Kohler D, Yanagawa, N, Pintille M, Li M, Panchal D, Pham N, Der S, Shepherd
FA, Tsao MS. Correlation of engraftment, mutation status, and response to chemotherapy
in primary tumor xenograft models of NSCLC. Presented at ASCO, Chicago, IL June
2010 J Clin Oncol 28, 15S: 727s, 2010.
39. Booth CM, Shepherd FA, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ. Adoption
of adjuvant chemotherapy for non-small cell lung cancer: A population-based outcomes
study. Presented at ASCO, Chicago, IL June 2010 J Clin Oncol 28, 15S: 519s, 2010.
40. Brade Am, Bezjak A, MacRae RM, Laurie SA, Wang L, Capobianco S, Shepherd FA. A
phase II study of concurrent pemetrexed/cisplatin/radiation (RT) for unresectable stage
IIIA/b non-small cell lung cancer (NSCLC). Presented at ASCO, Chicago, IL June 2010 J
Clin Oncol 28, 15S: 536s, 2010. .
41. Liu G, Cheng D, LeMaitre A, Liu N, Chen Z, Seymour L, Ding K, Shepherd FA, Tsao
MS. EGFR and ABCG2 polymorphisms as prognostic and predictive markers in the
NCIC CTG BR.21 trial of single-agent erlotinib and advanced non-small cell lung cancer
(NSCLC). Presented at ASCO, Chicago, IL June 2010 J Clin Oncol 28, 15S: 547s, 2010.
42. Coate LE, Massey C, Hope AJ, Pierre A, Bezjak A, Leighl NB, Darling GE, Sun A,
Keshavjee S, Shepherd FA. Treatment of the elderly when cure is the goal: the
influence of age on treatment selection and efficacy for stage III non-small cell lung
cancer (NSCLC). American Society of Clinical Oncology (ASCO) Annual Meeting,
Chicago. J Clin Oncol 28 (15 Suppl): 7014, 2010.
43. Carbone DP, Seymour L, Ding K, Roder H, Tsao MS, Shepherd FA. Serum proteomic
prediction of outcomes in advanced NSCLC patients treated with erlotinib/placebo in the
NCIC Clinical Trials Group BR.21 Trial. J Thoracic Oncol. 2010; 7: 18-19.
44. Horgan AM, Wang YV, Shepherd FA, Brenner D, Knox JJ, Liu G, Hung J. Then
interaction between smoking status and disease stage on non-small cell lung cancer
survival. J Clin Oncol 28, 15S: e18021, 2010.
45. Butts CA, Murray N, Maksymiuk A, Price A, Goss GD, et al, Shepherd FA, et al. L-
BLP25 treatment for advanced non-small cell lung cancer: safety data from a phase IIb
trial compared with an integrated safety analysis . J Clin Oncol 28, 15S: e13058
46. Feld R, Woo MM, Shepherd FA, Leighl NB, Elshtein R, Hengelage T, Hirawat S. A
drug interaction study between dextromethorphan and panobinostat (LBH 589) an orally
active deacetylase inhibitor, in patients with advanced cancer. J Clin Oncol 28, 15S:
e13089, 2010.
47. Brade A, Bezjak A, MacRae R, Laurie S, Cho J, Hope A, Sun A, Wang L, Capobianco S,
Iscoe N, Shepherd F. A phase II study of concurrent pemetrexed (P)/ cisplatin (C)/
radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC).
Canadian Association of Radiation Oncology (CARO) Annual Meeting, Vancouver.
Radiother Oncol 96(Supp 2): S19, A56, 2010.
48. Giuliani M, Sun A, Bezjak A, Le L, Brade A, Cho J, Leighl N, Shepherd FA, Hope
A. Patterns of failure in patients with limited-stage small cell lung carcinoma. Canadian
20

Association of Radiation Oncology (CARO) Annual Meeting, Vancouver. Radiother
Oncol 96(Supp 2): S59, A182, 2010.
49. Giuliani ME, Lindsay PE, Sun A, Bezjak A, Le LW, Brade A, Cho J, Leighl N,
Shepherd FA, Hope AJ. Patterns of failure in patients with limited-stage small cell lung
carcinoma. American Society of Radiation Oncology (ASTRO) Annual Meeting, San
Diego. Int J Radiat Oncol Biol Phys 78(Supp 3): S495, A2652, 2010.
50. Hope AJ, Coate LE, Massey C, Sacher A, Barrett K, Keshavjee S, Darling G, Leighl NB,
Bezjak A, Shepherd FA. Outcomes of bimodality and trimodality therapy in patients
with stage III non-small cell lung cancer (NSCLC). American Society of Radiation
Oncology (ASTRO) Annual Meeting, San Diego. Int J Radiat Oncol Biol Phys 78(Supp
3): S505, A2673, 2010.
51. Giuliani M, Lindsay PE, Brade AM, Sun A, Bezjak A, Shepherd FA, Hope A. Outcomes
of salvage therapy in patients with limited stage small cell lung cancer with isolated locoregional
failure. J Thorac Oncol 2010; 5: S550.
52. Ellis PM, Zhang J, Jones M, Jungnelius J, Shepherd FA. Phase I study of
pomalidomide
53. in combination with cisplatin and etoposide in extensive stage small cell lung cancer with
54. isolated loco-regional failure. J Thorac Oncol 2010; 5: S551.
55. Cuffe S. Ezzalfani M, Graziano S, Pignon JP, Seymour L, Strevel E, Burkes R,
Shepherd FA. A pooled exploratory analysis of the effect of tumour size on survival
benefit from platinum-based adjuvant chemotherapy in node negative non-small cell lung
cancer. J Thorac Oncol 2010; 5: S551.
56. Gauthier LR, Robert H. Dworkin, Ronald Melzack, G. Rodin, C. Zimmermann, D. Warr,
S.L. Librach, M. Moore, Shepherd FA, L. Gagliese. Age and gender-related patterns in
cancer pain severity and qualities. Presented at the Canadian Pain Society Conference,
April, 2010
57. Goss GD, Lorimer I, Tsao MS, O’Callaghan CJ, Ding K, Masters GA, Roberts P, Jett JR,
Edelman MJ, Shepherd FA. A phase III randomized, double-blind, placebo-controlled
trial of epidermal growth factor receptor inhibitor gefitinib in completely resected stage
IB-IIIA non-small cell lung cancer (NSCLC): NCIC BR.19. Presented at ASCO,
Chicago, IL June 2010.
58. John T, Kohler D, Yanagawa, N, Pintille M, Li M, Panchal D, Pham N, Der S, Shepherd
FA, Tsao MS. Correlation of engraftment, mutation status, and response to chemotherapy
in primary tumor xenograft models of NSCLC. Presented at ASCO, Chicago, IL June
2010.
59. Bezjak A, Leighl NB, GDarling GE, Sun A, Keshavjee S, Shepherd FA. Treatment of the
elderly when cure is the goal: the influence of age on treatment selection and efficacy for
stage III non-small cell lung cancer (NSCLC). Presented at ASCO, Chicago, IL June
2010.
60. Booth CM, Shepherd FA, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ. Adoption
of adjuvant chemotherapy for non-small cell lung cancer: A population-based outcomes
study. Presented at ASCO, Chicago, IL June 2010.
61. Brade Am, Bezjak A, MacRae RM, Laurie SA, Wang L, Capobianco S, Shepherd FA. A
phase II study of concurrent pemetrexed/cisplatin/radiation (RT) for unresectable stage
IIIA/b non-small cell lung cancer (NSCLC). Presented at ASCO, Chicago, IL June 2010.
62. Liu G, Cheng D, LeMaitre A, Liu N, Chen Z, Seymour L, Ding K, Shepherd FA, Tsao
MS. EGFR and ABCG2 polymorphisms as prognostic and predictive markers in the
NCIC CTG BR.21 trial of single-agent erlotinib and advanced non-small cell lung cancer
(NSCLC). Presented at ASCO, Chicago, IL June 2010
63. Coate LE, Massey C, Hope AJ, Pierre A, Bezjak A, Leighl NB, Darling GE, Sun A,
Keshavjee S, Shepherd FA. Treatment of the elderly when cure is the goal: the influence
21

of age on treatment selection and efficacy for stage III non-small cell lung cancer
(NSCLC). American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago. J
Clin Oncol 28(15 Suppl): 7014, 2010.
64. Brade A, Bezjak A, MacRae R, Laurie S, Cho J, Hope A, Sun A, Wang L, Capobianco S,
Iscoe N, Shepherd F. A phase II study of concurrent pemetrexed (P)/ cisplatin (C)/
radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC).
Canadian Association of Radiation Oncology (CARO) Annual Meeting, Vancouver.
Radiother Oncol 96(Supp 2): S19, A56, 2010.
65. Giuliani M, Sun A, Bezjak A, Le L, Brade A, Cho J, Leighl N, Shepherd F, Hope
A. Patterns of failure in patients with limited-stage small cell lung carcinoma. Canadian
Association of Radiation Oncology (CARO) Annual Meeting, Vancouver. Radiother
Oncol 96(Supp 2): S59, A182, 2010.
66. Giuliani ME, Lindsay PE, Sun A, Bezjak A, Le LW, Brade A, Cho J, Leighl N, Shepherd
FA, Hope AJ. Patterns of failure in patients with limited-stage small cell lung
carcinoma. American Society of Radiation Oncology (ASTRO) Annual Meeting, San
Diego. Int J Radiat Oncol Biol Phys 78(Supp 3): S495, A2652, 2010.
67. Hope AJ, Coate LE, Massey C, Sacher A, Barrett K, Keshavjee S, Darling G, Leighl NB,
Bezjak A, Shepherd FA. Outcomes of bimodality and trimodality therapy in patients
with stage III non-small cell lung cancer (NSCLC). American Society of Radiation
Oncology (ASTRO) Annual Meeting, San Diego. Int J Radiat Oncol Biol Phys 78(Supp
3): S505, A2673, 2010.
68. Cuffe S, Ezzalfani M, Graziano S, Pignon J, Seymour L, Strevel E, Burkes R, Shepherd
FA. A Pooled Exploratory Analysis of the Effect of tumor Size on Survival benefits from
Adjuvant Platinum-based Chemotherapy (ACT) in Node Negative (N0) Non-small Cell
Lung Cancer (NSCLC). Presented at the Chicago Multidsiciplinary Symposium in
Thoracic Oncology. Chicago 2010 J Thorac Oncol. S512.
69. Guiliani ME, Lindsay PE, Brade AM, Sun A, Bezjak A, Le LW, Cho J, Leighl N,
Shepherd FA, Hope AJ. Outcomes of Salvage Therapy in Patients with Limited-Stage
Small Cell Lung Carcinoma with Isolated Locoregional Failure. Presented at the Chicago
Multidsiciplinary Symposium in Thoracic Oncology. Chicago 2010 J Thorac Oncol.
S550
70. Ellis PM, Zhang J, Jones M, Jungnelius U, Shepherd FA. A Phae I Study of
Pomalidamide (CC-4047) in Combonation with Cisplatin and Etoposide in Patients with
Extensive Stage Small cell Lung Cancer (ES-SCLC). Presented at the Chicago
Multidsiciplinary Symposium in Thoracic Oncology. Chicago 2010 J Thorac Oncol.
S551.
71. Addison L, Ding K, Zhao H, Le Maitre A, Laurie SA, Goss G, Shepherd FA, Bradbusry
PA, Seymour L. Angiogenic factors and soluble receptors in NCIC CTG BR.24. J Clin
Oncol 29: 2011 (supp; abstr 3047)
72. Jotte R, Von Pawel J, Spigel DR, Socinscki MA,O’Brien M, Paschold EH , Mezger J,
Steins M, Bosquee L, Bubis JA, Nackaerts K, Trigo Perez JM, Clingan PR, Schuette W,
Lorigan P, Reck M, Domine M, Shepherd FA, McNally R, Renschler MF. Randomized
phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small
cell lung cancer (SCLC). J Clin Oncol 29: 2011 (supp; abstr 7000).
73. Michiels S, Mauguen A, Fisher D, Burdett S, Paulus R, Mandrekar SJ, Belani CP,
Shepherd FA, et al. Evaluation of disease-free survival as surrogate endpoint for overall
survival using two individual patient data meta-analyses of adjuvant chemotherapy in
operable non-small cell lung cancer. J Clin Oncol 29: 2011 (supp; abstr 7004)
74. Cuffe S, Booth CM, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ, Shepherd FA.
Adoption of adjuvant chemotherapy (ACT) for non-small cell lung cancer (NSCLC) in
22

the elderly: A population-based outcomes study. J Clin Oncol 29: 2011 (supp; abstr
7012).
75. Spigel DR, Harper PA, Hainsworth JD, De Marinis F, Kabbinavar FF, Kim ES, Lynch
TJ, Rosell R, Shepherd FA, Socincki MA. Randomized phase III trial of
gemcitabine/carboplatin with or withour iniparib (BSI-201) in patients with previously
untreated stage IV squamous non-small cell lung cancer (NSCLC). J Clin Oncol 29: 2011
(supp; abstr TPS220).
76. Hilton JF, Seymour L, Le Maitre A, Tu D, Shepherd FA, Bradbury PA. An evaluation of
the possible interaction of gastric acid suppressive medication and the EGFR tyrosine
kinase inhibitor erlotinib. J Clin Oncol 29: 2011 (supp; abstr 7523).
77. Sulpher JA, Owen SP, Hon H, Tobros K, Shepherd FA, et al. Factors influencing a
specific histological diagnosis of non-small cell lung cancer. J Clin Oncol 29: 2011
(supp; abstr 7541).
78. Soulieres D, Wold J, Shepherd FA, et al. Meta-analysis of the predictive and prognostic
value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small
cell lung cancer (NSCLC): Reccomendations of the BioLOGUE advisors. J Clin Oncol
29: 2011 (supp; abstr 7533).
79. Pintille M, Sykes J, Jurisica I, Shepherd FA, Tsao MS. Comparison of different
strategies for finding clinically useful signatures. Proc 32 nd Annual Conference of the
International Society for Clinical Biostatistics. Ottawa. 21-25 August 2011. P. 119
80. Booth CM, Shepherd FA, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ. Adoption of
adjuvant chemotherapy for non-small cell lung cancer: a population-based outcomes study.
Presented at ASCO, Chicago, Il, June 2011.
81. Cuffe S, Graziano S, Abderrahmane B, Pignon JP on behalf of the LACE BIO Group,
Ezzalfani M, Seymour, L, Strevel E, Burkes R, Capelletti M, Janne P, Tsao MS,
Shepherd FA. A pooled exploratory anaylysis of the impact of tumour size and KRAS
mutations on survival benefit from adjuvant platinum-based chemotherapy (ACT) in
node negative (NO) non-small cell lung cancer. Presented at the IASLC 14 th World
Conference on Lung Cancer, Amsterdam June 2011. J Thorac Oncol 2011; 6: S5462-63
82. Cuffe S, Booth C, Peng Y, Darling G, Li G, Kong W, Mackillop WJ, Shepherd FA.
Uptake of adjuvant chemotherapy, its tolerability and impact on survival among elderly
non-small cell lung cancer patients in Ontario: a population-based outcomes study.
Presented at the IASLC 14 th World Conference on Lung Cancer, Amsterdam June 2011.
J Thorac Oncol 2011; 6: S5463-64
83. Mauguen A, Michiels S, Burdett S, Tierney JF, Sause W, Mandrekar SJ, Dahlberg SE,
Shepherd FA, PArmar M, Perry MC, O’Brien M, Le Pechoux C, Pignon J-P, On behalf
of the Surrogate Project Collaborative Group. Evaluation of progression-free survival as a
suurogate endpoint for overall survival when evaluating the effect of chemotherapy and
radiotherapy in locally advanced lung cancer using data from four individual patient data
meta-analyses. Presented at the IASLC 14 th World Conference on Lung Cancer,
Amsterdam June 2011. J Thorac Oncol 2011; 6: S5464-65.
84. Novello S, Ramlau R, Gorbunova VA, Ciuleanu TE, Ozguroglu M, Goksel T, Baldotto
C, Bennoune J, Shepherd FA, Scagliotti G. Alfibercept in combination with docetaxel
for second-line treatment of locally advanced or metastatic non-small cell lung cancer
(NSCLC): Final results of multinational placebo-controlled phase III trial (EFC10261-
VITAL). Presented at the IASLC 14 th World Conference on Lung Cancer, Amsterdam
June 2011. J Thorac Oncol 2011; 6: S570.
85. Yanagawa N, Saieg MA, Kohler D, Sykes J, John T, Santod GDC, Pintile M, Shepherd
FA, Tsao MS. Apmlification of MYC abd aberrant expression of P53 and PTEN are
predictive of ability to form primary tumor zenografts in resected non-small cell lung
23

cancer. Presented at the IASLC 14 th World Conference on Lung Cancer, Amsterdam June
2011. J Thorac Oncol 2011; 6: S621-22
86. Goss GD, Addison CL, Ding K, Zhao H, Le Maitre A, Laurie S, Shepherd FA, Bradbury
PA, Seymour L. Circulation plasma angiogenic factors and soluble receptors in NCIC
CTG BR.24. Presented at the IASLC 14 th World Conference on Lung Cancer,
Amsterdam June 2011. J Thorac Oncol 2011; 6: S673.
87. Leighl N, Salvarrey A, Kassam F, Le L, Shepherd FA, Feld R, Tang F, Hollen P, Gralla
RJ. Preliminary report of a randomized trial computer-assisted quality of life assessment
in advanced NSCLC patients. Presented at the IASLC 14 th World Conference on Lung
Cancer, Amsterdam June 2011. J Thorac Oncol 2011; 6: S1120-21.
88. Laurie SA, Goss GD, Shepherd FA, Reaume N, Nicholas G, Philip L, Wang L, Oza A,
Hirsch V, Wright J, Leighl N. An inhibitor of SRC kinases, in platinum-preterated
advanced non-small cell lung cancer (NSCLC): a trial of the PMH Phase II Consortium.
Presented at the IASLC 14 th World Conference on Lung Cancer, Amsterdam June 2011.
J Thorac Oncol 2011; 6: S1262.
89. Guiliani ME, Lindsay PE, Sun A, Bezjak A, Le L, Brade A, Cho J, Leighl NB, Shepherd
FA, Hope A. Correlation of dosimetric factors in the development of esophagitis and
radiation pneumonitis in patients with limited stage non-small cell lung carcinoma.
Presented at the IASLC 14 th World Conference on Lung Cancer, Amsterdam June 2011.
J Thorac Oncol 2011; 6: S1348.
90. Brade AM, Bezjak A, MAcrae R, Laurie SA, Burkes R, Chu Q, Wang L, Goffin JR,
Grishma S, Capobianco S, Iscoe N, Shepherd FA. A phase II study evaluation
concurrent pemetrexed/cisplatin/radiation (RT) for unresectable stage III A/B non-small
cell lung cancer (NSCLC). Presented at the IASLC 14 th World Conference on Lung
Cancer, Amsterdam June 2011. J Thorac Oncol 2011; 6: S1543-44.
24